High BRE expression correlated with superior OS in intermediate- and poor-risk patients. (A) Kaplan-Meier plots for OS (left panels) and EFS (right panels) showed that MLL-AF9 positivity did not correlate significantly with a good OS or EFS among the intermediate- and poor-risk AML patients [ie, excluding patients with t(15;17), t(8;21), inv(16), and CEBPA double mutations; 5-year OS of 27.2 ± 2.4 vs 44.4 ± 11.7%, P = .17 and 5-year EFS of 20.2 ± 2.1 vs 44.4 ± 11.7%, P = .067 for MLL-AF9–negative and –positive patients, respectively]. (B) In the group of intermediate- and poor-risk AML patients, patients with high BRE expression exhibited a significantly better OS and EFS (5-year OS of 27.5 ± 2.3 vs 57.1 ± 13.2%, P = .04 and 5-year EFS of 20.0 ± 2.1 vs 57.1 ± 13.2%, P = .01 for patients with normal and high BRE expression, respectively). (C) Within the group of MLL-AF9–positive patients, high BRE expression correlated with a significantly better OS and EFS (5-year OS of 0% vs 80%, P = .0002 and 5-year EFS of 0% vs 80%, P = .0001 for patients with normal and high BRE expression, respectively). P values were determined with the log-rank test. The number of patients included in the analyses is shown in brackets.